TEM - Tempus AI, Inc. Class A Common Stock

TEM - Tempus AI, Inc. Class A Common Stock

https://www.tempus.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

What's Going On With Tempus AI Stock Monday? - Tempus AI ( NASDAQ:TEM )

Benzinga • 24 minutes ago • score: 0.16

Tempus AI stock is trading marginally lower on Monday. Recent bullish sentiment follows last Thursday's announcement that Tempus AI received 510 ( k ) clearance from the FDA. Up Next: Wall Street trader's 34-0 strategy goes public this week. See it first →

Tempus ( TEM ) Stock Jumps 13.6%: Will It Continue to Soar?

Zacks Commentary • 3 days, 3 hours ago • score: 0.41

Tempus (TEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Why Tempus AI Stock Soared Nearly 14% Higher Today

Motley Fool • 3 days, 17 hours ago • score: 0.35

The AI heathcare tech specialist is about to put another product on the market.

TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape

Zacks Commentary • 4 days, 3 hours ago • score: 0.31

Tempus AI's PurIST test secures clinical validation, helping personalize treatment choices for advanced pancreatic cancer patients.

Cathie Wood's Ark Dumps $2.1 Million Of This Hot AI Stock Despite Recent Acquisition Boost - ARK Genomic Revolution ETF ( BATS:ARKG ) , ARK Innovation ETF ( BATS:ARKK )

Benzinga • 5 days, 14 hours ago • score: 0.44

On Tuesday, Cathie Wood-led Ark Invest executed a significant trade involving Tempus AI Inc TEM. Ark Invest's decision to sell Tempus AI Inc TEM shares on Tuesday was executed through ARK Genomic Revolution ETF ARKG and ARK Innovation ETF ARKK. ARKG offloaded 6,309 shares, while ARKK sold 19,627 ...

What the Options Market Tells Us About Tempus AI - Tempus AI ( NASDAQ:TEM )

Benzinga • 5 days, 20 hours ago • score: 0.25

Deep-pocketed investors have adopted a bearish approach towards Tempus AI TEM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?

Zacks Commentary • 6 days, 3 hours ago • score: 0.24

Tempus AI posts 89.6% Q2 revenue growth, raises 2025 sales outlook again, and sees positive adjusted EBITDA ahead. What is the investment outlook?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.

52W High

$91.45

52W Low

$31.36

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

37.03

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

15.12

P/S (TTM) (<3 favorable)

14.53

P/B (<3 favorable)

44.68

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

41.83%

Institutions (25–75% balanced)

44.09%

Shares Outstanding

168,684,000

Float

104,417,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

951,981,000

Gross Profit (TTM)

578,145,000

EPS (TTM)

2.15

Profit Margin (>10% good)

-0.21%

Operating Margin (TTM) (higher better)

-0.19%

ROE (TTM) (>15% strong)

-0.98%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.90

Momentum

Bearish momentum

Value

5.5477

Previous

5.2316

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025